Background
Methods
Data sources and search strategy
Study eligibility
Data extraction and quality assessments
Statistical analysis
Results
Study characteristics
Study | Year | Country | Recruitment period | Prospective data collection | Inclusion and exclusion criteria | Definition of survival | Definition of LN density | Cut-off of LN density | Interpretation of LN density | Quality scale |
---|---|---|---|---|---|---|---|---|---|---|
Herr [5] | 2003 | USA | 1979–1999 | No | No | No | Yes | 20 | NA | 3 |
Fleischmann [18] | 2005 | Switzerland | 1985–2000 | Yes | Yes | Yes | No | 20 | NA | 5 |
Osawa [19] | 2009 | Japan | 1990–2005 | No | Yes | No | No | 25 | NA | 4 |
Wiesner [20] | 2009 | Germany | 2001–2006 | Yes | No | No | No | 11 | NA | 3 |
Furukawa [21] | 2010 | Japan | 1995–2003 | No | Yes | No | No | 25 | NA | 4 |
Guzzo [22] | 2010 | USA | 1988–2003 | Yes | Yes | No | Yes | 25 | NA | 5 |
Stephenson [23] | 2010 | USA | 1999–2007 | No | No | No | No | 20 | Blind | 3 |
May [24] | 2011 | Germany | 1989–2008 | No | Yes | No | Yes | 20 | NA | 5 |
Jensen [25] | 2012 | Denmark | 2004–2009 | Yes | Yes | Yes | Yes | 10 | NA | 6 |
Morgan [26] | 2012 | USA | 1992–2006 | No | Yes | Yes | Yes | 20 | NA | 4 |
Kassouf [27] | 2013 | Multination | 1993–2005 | No | Yes | Yes | No | None* | NA | 4 |
Masson-Lecomte [28] | 2013 | France | 2002–2011 | No | No | No | Yes | 20 | NA | 4 |
Mmeje [29] | 2013 | USA | 2005–2009 | No | No | Yes | Yes | 20 | NA | 4 |
Kwon [30] | 2014 | Korea | 1990–2011 | No | Yes | Yes | No | 18 | NA | 4 |
Study | No. of patients | Median age, range (years) | Gender (male/female) | Upper limit of PLND | Neoadjuvant chemotherapy | Adjuvant chemotherapy | Median Follow-up, range (months) |
---|---|---|---|---|---|---|---|
Herr [5] | 162 | 67 (36–87) | NA | Distal common iliac artery | 0 | NA | 90 (24–180) |
Fleischmann [18] | 101 | 67 (35–89) | 87/14 | Crossing of the ureter with common iliac artery | 0 | 41 | 21 (1–191) |
Osawa [19] | 60 | 68 (34–84) | 48/12 | Below the bifurcation of common iliac artery (almost) Above iliac bifurcation (a few) | 0 | 25 | 41 (4–138) |
Wiesner [20] | 46 | NA | NA | Inferior mesenteric artery | 0 | 27 | 22 (1–76) |
Furukawa [21] | 82 | 70.3 (42–86) | 62/20 | Distal common iliac artery | 0 | 17 | 33.6 (mean) (2–142) |
Guzzo [22] | 85 | NA | 67/18 | Bifurcation of common iliac artery | 0 | 55 | 46 (3–223) |
Stephenson [23] | 134 | 68 (IQR: 59–75) | NA | Distal common iliac artery | 0 | 90 | 23 (IQR: 10–36) |
May [24] | 477 | 66.3 (33–86) | 376/101 | NA | 0 | 159 | 16 |
Jensen [25] | 43 | NA | NA | Inferior mesenteric artery | 0 | 0 | 53 (24–83) |
Morgan [26] | 779 | NA | 530/249 | NA | 28 | 296 | NA |
Kassouf [27] | 1,038 | 67 (IQR: 60–73) | 821/217 | Not standardized | 0 | NA | 33 (IQR: 14–69) |
Masson-Lecomte [28] | 75 | 65 (31–85) | 64/11 | Common iliac bifurcation | NA | 46 | 40.6 (3–127) |
Mmeje [29] | 50 | 69 (mean) (50–83) | 38/12 | Aortic bifurcation | 29 | 19 | 39.6 (16–75) |
Kwon [30] | 179 | NA | NA | Not standardized | 0 | NA | 64.3 (1–231.4) |
Study | Tumor grade (G0/G1/G2/G3) | Pathologic T stage (pT0/is/a/1/2/3/4) | Pathologic N stage (pN1/2/3) | Median no. of LNs removed, range | Median no. of positive LNs, range | Median LN density, range (%) |
---|---|---|---|---|---|---|
Herr [5] | NA | 79 (≤T2)/123/0 | 54/87/21 | 13 (2–32) | 3.3 | NA |
Fleischmann [18] | NA | 0/0/0/19 (T1/2)/53/30 | 32/69/0 | 22 (10–43) | NA | NA |
Osawa [19] | 0/0/9/51 | 0/0/0/1/6/38/15 | 21/39 | 12 (1–80) | 2 (1–12) | 23.1 (1.3-100) |
Wiesner [20] | 0/0/8/38 | 0/0/0/3/11/24/8 | NA | 33 (15–77) | 3 (1–28) | 11 (1–73) |
Furukawa [21] | 0/0/12/70 | 0/0/0/0/19/37/26 | 32/50/0 | 14.4 (mean) (6–37) | 3.1 (mean) (1–12) | 25.3 (2.8–100) |
Guzzo [22] | NA | 9 (≤T1)/13/63 (T3/4) | NA | 16.7 (mean) (5–56) | NA | NA |
Stephenson [23] | NA | 107 (≤T2)/27 (T3/4) | 62/72 (N2/3) | 14 (IQR: 9–20) | 2 (IQR: 1–3) | 17 (IQR: 9–38) |
May [24] | 79 (≤G2)/398 | 24 (≤T1)/103/350 (T3/4) | 187/290/0 | 12 (1–66) | 2 (1–25) | 17.6 (2.3–100) |
Jensen [25] | NA | NA | 16/9/18 | NA | NA | NA |
Morgan [26] | 27 (LG)/741 (HG) | 14 (≤T1)/48/131/585 | NA | 9 (IQR: 4–16) | 2 (IQR: 1–3) | 25 (IQR: 13–50) |
Kassouf [27] | NA | 65 (≤T1)/176/505/292 | NA | 18 (IQR: 11–32) | 2 (IQR: 1–5) | 14.3 (IQR: 6.7–33.3) |
Masson-Lecomte [28] | NA | 0/0/0/2/15/39/19 | 10/10/6 | 18 (3–49) | 3 (1–35) | 19 (2–100) |
Mmeje [29] | NA | 0/1/0/2/13/26/7 | NA | 19 (mean) (5–35) | 3 (mean) (1–12) | NA |
Kwon [30] | NA | NA | 62/116/1 | 16 (1–118) | 3 (1–37) | 17.6 (2.6–100) |
Outcomes from eligible studies
Study | HR estimation | Co-factors | Analysis results |
---|---|---|---|
Fleischmann [18] | HR, 95 % CI | Extracapsular extension, no. of positive LNs | Not significant |
Guzzo [22] | HR, 95 % CI | Age, sex, diversion type, pT stage, adjuvant chemotherapy | Not significant |
Jensen [25] | HR, 95 % CI | Age, sex, pT stage, pN stage, metasis above the aortic bifurcation, extracapsular extension, volume dependent LN density, diameter of largest LN, volume of metastatic LNs | Not significant |
Masson-Lecomte [28] | HR, 95 % CI | pT stage, lymphovascular invasion, extracapsular extension, adjuvant chemoethrapy | Significant |
Mmeje [29] | P value, event no. (univariate) | - | Not significant |
Kwon [30] | HR, 95 % CI | pT stage, pN stage, no. of positive LNs, adjuvant chemotherapy | Not significant |
Study | HR estimation | Co-factors | Analysis results |
---|---|---|---|
Herr [5] | P value, event no. | pT stage, pN stage, no. of LNs removed, no. of positive LNs | Significant |
Wiesner [20] | HR, 95 % CI | No. of LNs removed, no. of positive LNs | Significant |
Furukawa [21] | HR, 95 % CI | No. of positive LNs, laterality of positive LNs, adjuvant chemotherapy | Significant |
Guzzo [22] | HR, 95 % CI | Age, sex, diversion type, pT stage, adjuvant chemotherapy | Not significant |
May [24] | HR, 95 % CI | Age, sex, radical cystectomy time frame, pT stage, pN stage, tumor grade, concomitant carcinoma in situ, adjuvant chemotherapy, no. of LNs removed | Significant |
Jensen [25] | HR, 95 % CI | Age, sex, pT stage, pN stage, metastasis above the aortic bifurcation, extracapsular extension, volume dependent LN density, diameter of largest LN, volume of metastatic LNs | Not significant |
Morgan [26] | HR, 95 % CI | Age, Charlson comorbidity index, pT stage, tumor grade, no. of LNs removed, adjuvant chemotherapy, diversion type, year of surgery, surgeon volume, transfusion | Significant |
Kassouf [27] | HR, 95 % CI | Age, sex, tumor grade, pT stage, margin status, lymphovascular invasion, adjuvant chemotherapy, concomitant carcinoma in situ | Significant |
Masson-Lecomte [28] | P value, event no. | pT stage, extracapsular extension, adjuvant chemoethrapy | Not significant |
Kwon [30] | HR, 95 % CI | pT stage, pN stage, no. of positive LNs, adjuvant chemotherapy | Not significant |
Study | HR estimation | Co-factors | Analysis results |
---|---|---|---|
Osawa [19] | HR, 95 % CI | Histology, no. of positive LNs, adjuvant chemotherapy | Significant |
Guzzo [22] | HR, 95 % CI | Age, sex, diversion type, pT stage, adjuvant chemotherapy | Not significant |
Stephenson [23] | HR, 95 % CI | pT stage, aggregate LN metastasis diameter, lymphovascular invasion, margin status, extracapsular extension | Not significant |
Morgan [26] | HR, 95 % CI | Age, Charlson comorbidity index, pT stage, tumor grade, no. of LNs removed, adjuvant chemotherapy, diversion type, year of surgery, surgeon volume, transfusion | Significant |
Mmeje [29] | P value, event no. (univariate) | - | Not significant |
No. of included articles | No. of cases | Pooled HR (95 % CI) | Chi2 (p value) | I2 | Ph* | |
---|---|---|---|---|---|---|
Publication year | 0.0517 | |||||
2003–2010 | 4 | 375 | 1.61 (1.09–2.38) | 7.42 (0.06) | 60 % | |
2011–2014 | 6 | 2591 | 1.51 (1.16–1.97) | 12.22 (0.03) | 59 % | |
Region | 0.3206 | |||||
USA | 3 | 1979 | 1.57 (1.10–2.22) | 11.45 (0.003) | 83 % | |
Europe | 5 | 1679 | 1.54 (1.02–2.31) | 14.19 (0.007) | 72 % | |
Asia | 2 | 261 | 1.61 (1.08–2.39) | 0.46 (0.5) | 0 % | |
No. of patients | 0.0015 | |||||
<100 | 5 | 331 | 1.40 (0.82–2.40) | 12.35 (0.01) | 68 % | |
≥100 | 5 | 2635 | 1.55 (1.23–1.95) | 14.06 (0.007) | 72 % | |
Median follow-up* | 0.0017 | |||||
<36 months | 4 | 1643 | 1.85 (1.53–2.24) | 2.58 (0.46) | 0 % | |
≥36 months | 5 | 544 | 1.20 (0.91–1.59) | 7.43 (0.11) | 46 % | |
Analysis results | 0.1626 | |||||
Not significant | 4 | 382 | 1.14 (0.69–1.87) | 7.37 (0.06) | 59 % | |
Significant | 6 | 2584 | 1.69 (1.31–2.17) | 18.98 (0.002) | 74 % | |
Quality scale | 0.0233 | |||||
≤4 | 7 | 2361 | 1.60 (1.26–2.03) | 16.99 (0.009) | 65 % | |
>4 | 3 | 605 | 1.08 (0.51–2.30) | 8.91 (0.01) | 78 % |